ROVI Stock Analysis: Laboratorios Farmaceuticos | MC
Drug Manufacturers - Specialty & Generic | MC, Spain | Market Cap: 2.997m EUR | 12M Return: 5.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.94M
EPS Trend: -78.5%
Rev. Trend: -79.3%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Laboratorios Farmaceuticos Rovi, S.A. is a Spanish pharmaceutical company founded in 1946 and headquartered in Pozuelo de Alarcón, Spain. Listed on the Madrid Stock Exchange under the ticker ROVI, the company operates as a subsidiary of Norbel Inversiones, S.L. Its operations span Spain, the European Union, OECD countries, and other international markets.
ROVI operates across three main business areas: a portfolio of proprietary prescription products (including Enoxaparin Rovi, a low-molecular-weight heparin), hospital and diagnostic imaging products (such as Iomeron, Iopamiro, and Sonovue contrast agents), and a contract development and manufacturing (CDMO) business focused on injectables in prefilled syringes, vials, and cartridges. The CDMO segment offers services including sterile filling, terminal sterilisation, serialisation, and aggregation, serving third-party pharmaceutical clients. Its products address therapeutic areas including cardiology, womens health, anesthesia/pain, diagnostic imaging, central nervous system, urology, endocrinology, respiratory, and primary care.
The Spanish pharmaceutical industry is one of the largest in Europe, with the country hosting a significant number of GMP-certified manufacturing facilities serving both domestic and export markets. Injectable contract manufacturing in particular is a capital-intensive segment, requiring specialised aseptic processing capabilities and regulatory compliance across multiple jurisdictions.
- Moderna vaccine contract cancellation pressures contract manufacturing revenue
- Enoxaparin biosimilar competition erodes prescription product margins
- Risperidone QUAR and Okedi launches expand specialty injectable portfolio
| Net Income: 185.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 7.39 > 1.0 |
| NWC/Revenue: 37.70% < 20% (prev 44.03%; Δ -6.33% < -1%) |
| CFO/TA 0.22 > 3% & CFO 252.7m > Net Income 185.2m |
| Net Debt (9.34m) to EBITDA (266.1m): 0.04 < 3 |
| Current Ratio: 2.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.1m) vs 12m ago 0.0% < -2% |
| Gross Margin: 64.02% > 18% (prev 62.40%; Δ 1.62% > 0.5%) |
| Asset Turnover: 77.44% > 50% (prev 86.13%; Δ -8.70% > 0%) |
| Interest Coverage Ratio: 54.42 > 6 (EBIT TTM 232.5m / Interest Expense TTM 4.27m) |
| A: 0.26 (Total Current Assets 568.0m - Total Current Liabilities 276.5m) / Total Assets 1.13b |
| B: 0.54 (Retained Earnings 613.4m / Total Assets 1.13b) |
| C: 0.23 (EBIT TTM 232.5m / Avg Total Assets 998.3m) |
| D: 1.71 (Book Value of Equity 700.6m / Total Liabilities 410.0m) |
| Altman-Z'' = 6.83 = AAA |
| DSRI: 1.14 (Receivables 160.3m/136.3m, Revenue 773.1m/749.0m) |
| GMI: 0.97 (GM 62.40% / 64.02%) |
| AQI: 0.96 (AQ_t 0.07 / AQ_t-1 0.07) |
| SGI: 1.03 (Revenue 773.1m / 749.0m) |
| TATA: -0.06 (NI 185.2m - CFO 252.7m) / TA 1.13b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of July 29, 2026, the stock is trading at EUR 59.25 with a total of 143,351 shares traded. Over the past week, the price has changed by +9.62%, over one month by +2.36%, over three months by -25.55% and over the past year by +5.60%.
Current recommended Stop Loss: 56.40 (which is 4.8% or 2.1 ATR below the current price).
Laboratorios Farmaceuticos has no consensus analysts rating.
P/E Trailing = 22.7132
P/E Forward = 36.63
P/S = 4.044
P/B = 4.265
P/EG = 1.2569
Revenue TTM = 773.1m EUR
EBIT TTM = 232.5m EUR
EBITDA TTM = 266.1m EUR
Long Term Debt = 83.9m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 28.5m EUR (from shortTermDebt, last fiscal year)
Debt = 137.4m EUR (from shortLongTermDebtTotal, last fiscal year) + Leases 15.7m
Net Debt = 9.34m EUR (calculated: Debt 137.4m - CCE 128.1m)
Enterprise Value = 3.01b EUR (3.00b + Debt 137.4m - CCE 128.1m)
Interest Coverage Ratio = 54.42 (Ebit TTM 232.5m / Interest Expense TTM 4.27m)
EV/FCF = 17.01x (Enterprise Value 3.01b / FCF TTM 176.8m)
FCF Yield = 5.88% (FCF TTM 176.8m / Enterprise Value 3.01b)
FCF Margin = 22.87% (FCF TTM 176.8m / Revenue TTM 773.1m)
Net Margin = 23.95% (Net Income TTM 185.2m / Revenue TTM 773.1m)
Gross Margin = 64.02% ((Revenue TTM 773.1m - Cost of Revenue TTM 278.1m) / Revenue TTM)
Gross Margin QoQ = 68.68% (prev 55.56%)
Tobins Q-Ratio = 2.67 (Enterprise Value 3.01b / Total Assets 1.13b)
Interest Expense / Debt = 3.11% (Interest Expense 4.27m / Debt 137.4m)
Taxrate = 21.33% (50.2m / 235.2m)
NOPAT = 182.9m (EBIT 232.5m * (1 - 21.33%))
Current Ratio = 2.05 (Total Current Assets 568.0m / Total Current Liabilities 276.5m)
Debt / Equity = 0.20 (Debt 137.4m / totalStockholderEquity, last quarter 700.6m)
Debt / EBITDA = 0.04 (Net Debt 9.34m / EBITDA 266.1m)
Debt / FCF = 0.05 (Net Debt 9.34m / FCF TTM 176.8m)
Total Stockholder Equity = 665.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.55% (Net Income 185.2m / Total Assets 1.13b)
RoE = 27.84% (Net Income TTM 185.2m / Total Stockholder Equity 665.2m)
RoCE = 31.04% (EBIT 232.5m / Capital Employed (Equity 665.2m + L.T.Debt 83.9m))
RoIC = 21.77% (NOPAT 182.9m / Invested Capital 840.3m)
WACC = 6.79% (E(3.00b)/V(3.13b) * Re(6.99%) + D(137.4m)/V(3.13b) * Rd(3.11%) * (1-Tc(0.21)))
Discount Rate = 6.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -55.32 | Cagr: -0.14%
[DCF] Terminal Value 77.97% ; FCFF base≈134.9m ; Y1≈154.7m ; Y5≈227.6m
[DCF] Fair Price = 66.80 (EV 3.43b - Net Debt 9.34m = Equity 3.42b / Shares 51.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -78.53 | EPS CAGR: -11.24% | SUE: N/A | # QB: 0
Revenue Correlation: -79.26 | Revenue CAGR: -3.79% | SUE: 2.22 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=2.52 | Chg30d=-1.34% | Revisions=-67% | GrowthEPS=-8.2% | GrowthRev=+3.6%
EPS next Year (2027-12-31): EPS=3.39 | Chg30d=-2.26% | Revisions=-70% | GrowthEPS=+34.4% | GrowthRev=+15.6%
[Analyst] Revisions Ratio: -81% (up=0, down=13)